A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease

Annals of the Rheumatic Diseases

Volumn 71, Issue 8, 2012, Pages 1374-1381

  Pratt, Arthur G ^a,b   Swan, Daniel C ^c   Richardson, Sarah ^a   Wilson, Gillian ^b   Hilkens, Catharien M U ^a   Young, David A ^a   Isaacs, John D ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 6; STAT3 PROTEIN;

ADULT; AGED; ARTHRITIS; ARTICLE; BCL3 GENE; CD4+ T LYMPHOCYTE; CMAH GENE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GPRIN3 GENE; HUMAN; ID3 GENE; IGFL2 GENE; LDHA GENE; LEIDEN SCORE; LOC731186 GENE; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MUC1 GENE; NOG GENE; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PATHOGENESIS; PDCD1 GENE; PIM1 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SBNO2 GENE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SOCS3 GENE; VALIDATION STUDY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; EARLY DIAGNOSIS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84863856487     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200968     Document Type: Article

References (43)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
2. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45. (Pubitemid 46044858)
3. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15. (Pubitemid 38326168)
4. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
5. van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008;58:2241-7.
6. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808. (Pubitemid 351650500)
7. Pratt AG, Isaacs JD, Wilson G. The clinical utility of a rule for predicting rheumatoid arthritis in patients with early undifferentiated arthritis: comment on the article by van der Helm-van Mil et al. Arthritis Rheum 2009;60:905; author reply 906.
8. Pascual V, Chaussabel D, Banchereau J. A genomic approach to human autoimmune diseases. Annu Rev Immunol 2010;28:535-71.
9. McKinney EF, Lyons PA, Carr EJ, et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010;16:586-91, 1p following 591.
10. van Baarsen LG, Bos WH, Rustenburg F, et al. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 2010;62:694-704.
11. Batliwalla FM, Baechler EC, Xiao X, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005;6:388-97. (Pubitemid 43090514)
12. Lyons PA, Koukoulaki M, Hatton A, et al. Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. BMC Genomics 2007;8:64.
13. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010;69:1898-906.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
15. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006;7:3.
16. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-27. (Pubitemid 44906106)
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
18. Cortes C, Vapnik V. Support-vector networks. Machine Learning 1995;20:273-97.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. (Pubitemid 34164012)
20. Owaki T, Asakawa M, Morishima N, et al. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol 2008;180:2903-11.
21. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21. (Pubitemid 27289594)
22. El Kasmi KC, Smith AM, Williams L, et al. Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. (erratum appears in J Immunol 2008;180:3612 Note: Panopolous, Athanasia (corrected to Panopoulos, Athanasia D)). J Immunol 2007;179:7215-9.
23. Brocke-Heidrich K, Ge B, Cvijic H, et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 2006;25:7297-304. (Pubitemid 44809095)
24. Richard M, Louahed J, Demoulin JB, et al. Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction. Blood 1999;93:4318-27. (Pubitemid 29279275)
25. Gao J, McConnell MJ, Yu B, et al. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 2009;35:337-45.
26. Akaishi H, Takeda K, Kaisho T, et al. Defective IL-2-mediated IL-2 receptor alpha chain expression in Stat3-deficient T lymphocytes. Int Immunol 1998;10:1747-51. (Pubitemid 28502389)
27. Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999;93:1980-91. (Pubitemid 29128500)
28. Nichane M, Ren X, Bellefroid EJ. Self-regulation of Stat3 activity coordinates cell-cycle progression and neural crest specification. EMBO J 2010;29:55-67.
29. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56. (Pubitemid 30339210)
30. Nowell MA, Williams AS, Carty SA, et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009;182:613-22.
31. Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36. (Pubitemid 44835496)
32. Eyles JL, Hickey MJ, Norman MU, et al. A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood 2008;112:5193-201.
33. Rho YH, Solus J, Sokka T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009;60:1906-14.
34. El Kasmi KC, Smith AM, Williams L et al. Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. (Erratum appears in J Immunol 2008;180:3612 Note: Panopolous, Athanasia (corrected to Panopoulos, Athanasia D)). J Immunol 2007;179:7215-9.
35. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ 1994;309:102. (Pubitemid 24216428)
36. Ponchel F, Morgan AW, Bingham SJ, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002;100:4550-6. (Pubitemid 35429697)
37. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005;204:55-73. (Pubitemid 40460493)
38. Kokkonen H, Söderström I, Rocklöv J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010;62:383-91.
39. Karlson EW, Chibnik LB, Tworoger SS, et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum 2009;60:641-52.
40. Schindler CW. Series introduction. JAK-STAT signaling in human disease. J Clin Invest 2002;109:1133-7. (Pubitemid 34496589)
41. Fonseca JE, Santos MJ, Canhão H, et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538-42.
42. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4.
43. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 2010;22:330-5.